Filter Results:
(60)
Show Results For
- All HBS Web (100)
- Faculty Publications (25)
Show Results For
- All HBS Web (100)
- Faculty Publications (25)
Sort by
- 10 Mar 2015
- First Look
First Look: March 10
working paper: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2397317 Cases & Course Materials Harvard Business School Case 515-042 Simplot Plant Sciences: Designing a Better Potato Privately held Simplot has developed a new View Details
Keywords: Carmen Nobel
- September 2020
- Case
Minerva 2020: Clinical Trials
By: John R. Wells and Benjamin Weinstock
In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results... View Details
Keywords: Biotechnology; Strategic Decision Making; Entrepreneurship; Health Testing and Trials; Decision Choices and Conditions; Strategy
Wells, John R., and Benjamin Weinstock. "Minerva 2020: Clinical Trials." Harvard Business School Case 721-391, September 2020.
- 2008
- Chapter
The Evidence Does Not Speak for Itself: Expert Witnesses and the Organization of DNA-Typing Companies
By: Arthur A. Daemmrich
During the past 15 years, new biotechnology companies have promoted DNA typing as a sophisticated criminal and paternity identification technique. Private testing laboratories produce results that link individuals with crime scenes and fathers to their children.... View Details
- 20 Jul 2011
- Research & Ideas
Five Discovery Skills that Distinguish Great Innovators
that distinguish innovative entrepreneurs and executives from run-of-the-mill managers. What Makes Innovators Different? So what makes innovators different from the rest of us? Most of us believe this question has been answered. It's a View Details
- 21 Jan 2014
- First Look
First Look: January 21
out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details
Keywords: Sean Silverthorne
- 13 Jan 2009
- First Look
First Look: January 13, 2009
Should this gene detection firm enter the business of providing tests for the detection of genetic diseases? If so, how should it prioritize the tests it could develop?... View Details
Keywords: Martha Lagace
- February 2024
- Article
Are Many Sex/Gender Differences Really Power Differences?
By: Adam D. Galinsky, Aurora Turek, Grusha Agarwal, Eric M. Anicich, Derek D. Rucker, Hannah Riley Bowles, Nira Liberman, Chloe Levin and Joe C Magee
This research addresses the long-standing debate about the determinants of sex/gender differences. Evolutionary theorists trace many sex/gender differences back to natural selection and sex-specific adaptations. Sociocultural and biosocial theorists, in contrast,... View Details
Galinsky, Adam D., Aurora Turek, Grusha Agarwal, Eric M. Anicich, Derek D. Rucker, Hannah Riley Bowles, Nira Liberman, Chloe Levin, and Joe C Magee. "Are Many Sex/Gender Differences Really Power Differences?" PNAS Nexus 3, no. 2 (February 2024).
- 21 Feb 2005
- Op-Ed
Is Business Management a Profession?
since the Middle Ages by the rise and ongoing progress of modern science. The development of the germ theory of disease in the nineteenth century, for example, and of the science of genetics in the twentieth, have gone into the formation... View Details
- 08 Sep 2008
- HBS Case
The Value of Environmental Activists
There are many methods, most financial, to measure the success of companies in meeting goals. But the question becomes a lot harder at Harvard Business School when MBAs are challenged to measure the efforts of environmental organizations like Greenpeace and the World... View Details
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
drugs, and will they be less expensive?' My answer is, 'I don't know, and probably not.' Lechleiter was one of several panelists to discuss, "Breaking the Genetic Code: The Business of Life Science in the 21st Century" at the... View Details
Keywords: by Sean Silverthorne
- 15 Apr 2014
- First Look
First Look: April 15
Pooled Income Funds. Purchase this case: http://hbr.org/product/choosing-a-charitable-giving-vehicle/an/314073-PDF-ENG Harvard Business School Case 514-086 23andMe: Genetic Testing for Consumers (A) On... View Details
Keywords: Sean Silverthorne
- 17 Nov 2003
- Research & Ideas
The Business of Babies
Chinese babies), and international restrictions and legislation concerning adoption. High-tech measures include IVF, artificial insemination, surrogacy, gamete interfallopian transfer (GIFT) in which the sperm is injected directly into the fallopian tube,... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- 14 Jul 2009
- First Look
First Look: July 14
Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details
Keywords: Martha Lagace
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family... View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 03 Mar 2015
- First Look
First Look: March 3
Customers could pay to access the database for research, to create genetic tests, or for many other purposes. GenapSys would also build an online store with the genetic tests... View Details
Keywords: Sean Silverthorne
- 07 Aug 2006
- Research & Ideas
Whatever Happened to Caveat Emptor?
Its early milestones—comparative product tests launched by Consumer Reports in 1936, the Kennedy administration's Consumer Bill of Rights in 1960, Ralph Nader's critique of the U.S. automobile industry in Unsafe at Any Speed in... View Details
- 23 Nov 2010
- First Look
First Look: November 23
School Case 811-014 The Ze-gen case covers the first five years in the life of a clean-tech start-up. Ze-gen had developed an innovative technology that converted solid waste into synthesis gas (called syngas). This technology was in View Details
Keywords: Sean Silverthorne
- 23 Mar 2016
- Research & Ideas
Researchers Prove C-Suite Gender Gap—but Can’t Explain It
that male and female executives sharing equal attributes neither have the same probability of reaching the top, nor are they paid equally” The worse news is there doesn’t seem to be much women can do to close that gap—no matter how talented, educated, skilled, lucky,... View Details
Keywords: by Carmen Nobel